S&P 500   3,087.01 (-0.20%)
DOW   27,691.49 (+0.04%)
QQQ   200.96 (-0.13%)
CGC   20.30 (-5.41%)
BABA   186.71 (-0.24%)
GE   11.35 (-1.48%)
F   9.08 (+0.44%)
ACB   3.62 (-4.99%)
PRI   129.23 (-0.37%)
BAC   33.18 (-0.24%)
DIS   136.74 (-0.88%)
S&P 500   3,087.01 (-0.20%)
DOW   27,691.49 (+0.04%)
QQQ   200.96 (-0.13%)
CGC   20.30 (-5.41%)
BABA   186.71 (-0.24%)
GE   11.35 (-1.48%)
F   9.08 (+0.44%)
ACB   3.62 (-4.99%)
PRI   129.23 (-0.37%)
BAC   33.18 (-0.24%)
DIS   136.74 (-0.88%)
Log in

Actinium Pharmaceuticals Stock Price, Forecast & Analysis (NYSEAMERICAN:ATNM)

$0.25
-0.01 (-3.85 %)
(As of 11/11/2019 04:00 PM ET)
Today's Range
$0.25
Now: $0.25
$0.27
50-Day Range N/A
52-Week Range
$0.19
Now: $0.25
$0.71
Volume1.17 million shs
Average Volume1.21 million shs
Market Capitalization$40.61 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Actinium Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:ATNM
CUSIPN/A
CIKN/A
Phone+1-646-6773875

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees30
Market Cap$40.61 million
Next Earnings DateN/A
OptionableOptionable

Receive ATNM News and Ratings via Email

Sign-up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter.


Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Frequently Asked Questions

What is Actinium Pharmaceuticals' stock symbol?

Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM."

How were Actinium Pharmaceuticals' earnings last quarter?

Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) announced its quarterly earnings data on Monday, March, 16th. The biotechnology company reported ($0.17) EPS for the quarter, topping the Zacks' consensus estimate of ($0.19) by $0.02. View Actinium Pharmaceuticals' Earnings History.

What price target have analysts set for ATNM?

4 equities research analysts have issued twelve-month target prices for Actinium Pharmaceuticals' stock. Their forecasts range from $1.50 to $6.00. On average, they expect Actinium Pharmaceuticals' stock price to reach $4.17 in the next year. This suggests a possible upside of 1,566.7% from the stock's current price. View Analyst Price Targets for Actinium Pharmaceuticals.

What is the consensus analysts' recommendation for Actinium Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Actinium Pharmaceuticals.

What are Wall Street analysts saying about Actinium Pharmaceuticals stock?

Here are some recent quotes from research analysts about Actinium Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company's principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. " (10/15/2019)
  • 2. Maxim Group analysts commented, "Actinium reported 4Q18 and FY18 with a net loss of ($6.4M) and ($23.7M), respectively. The company ended the year with $13.6M in cash on the balance sheet (not including $2.5M warrant exercises). The company also has a $30M ATM in place. Combined, the company should have sufficient runway to get the P3 data for Iomab in 1H20." (3/20/2019)

Has Actinium Pharmaceuticals been receiving favorable news coverage?

News articles about ATNM stock have been trending very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Actinium Pharmaceuticals earned a coverage optimism score of -3.2 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Actinium Pharmaceuticals.

Are investors shorting Actinium Pharmaceuticals?

Actinium Pharmaceuticals saw a decrease in short interest during the month of October. As of October 31st, there was short interest totalling 2,870,000 shares, a decrease of 18.2% from the September 30th total of 3,510,000 shares. Based on an average daily trading volume, of 874,200 shares, the short-interest ratio is presently 3.3 days. Currently, 1.8% of the company's stock are short sold. View Actinium Pharmaceuticals' Current Options Chain.

Who are some of Actinium Pharmaceuticals' key competitors?

What other stocks do shareholders of Actinium Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP), Fitbit (FIT), Global Ship Lease (GSL), Opko Health (OPK), TransEnterix (TRXC), Tandem Diabetes Care (TNDM), Sorrento Therapeutics (SRNE), Synergy Pharmaceuticals (SGYP), Cancer Genetics (cgix) and AK Steel (AKS).

Who are Actinium Pharmaceuticals' key executives?

Actinium Pharmaceuticals' management team includes the folowing people:
  • Mr. Sandesh C. Seth, Chairman & CEO (Age 55)
  • Mr. Steven O'Loughlin BS, Principal Financial & Accounting Officer (Age 33)
  • Dr. Dale L. Ludwig Ph.D., Chief Scientific Officer (Age 57)
  • Dr. Mark S. Berger, Chief Medical Officer (Age 64)
  • Mr. Anil Kapur, Chief Commercial Officer (Age 50)

How do I buy shares of Actinium Pharmaceuticals?

Shares of ATNM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Actinium Pharmaceuticals' stock price today?

One share of ATNM stock can currently be purchased for approximately $0.25.

How big of a company is Actinium Pharmaceuticals?

Actinium Pharmaceuticals has a market capitalization of $40.61 million. Actinium Pharmaceuticals employs 30 workers across the globe.View Additional Information About Actinium Pharmaceuticals.

What is Actinium Pharmaceuticals' official website?

The official website for Actinium Pharmaceuticals is http://www.actiniumpharmaceuticals.com/.

How can I contact Actinium Pharmaceuticals?

Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The biotechnology company can be reached via phone at +1-646-6773875.


MarketBeat Community Rating for Actinium Pharmaceuticals (NYSEAMERICAN ATNM)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  274 (Vote Outperform)
Underperform Votes:  146 (Vote Underperform)
Total Votes:  420
MarketBeat's community ratings are surveys of what our community members think about Actinium Pharmaceuticals and other stocks. Vote "Outperform" if you believe ATNM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATNM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/11/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel